REVELATION BIOSCIENCES, INC. Operating Lease, Expense
REVELATION BIOSCIENCES, INC. (REVB) reported Operating Lease, Expense of $64.20 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2025-03-06
- REVELATION BIOSCIENCES, INC. operating lease, expense for the quarter ending 2024-12-31 was $16.05K, a 44.44% decline year-over-year.
- REVELATION BIOSCIENCES, INC. operating lease, expense for the quarter ending 2024-09-30 was $16.05K, a 44.44% decline year-over-year.
- REVELATION BIOSCIENCES, INC. operating lease, expense for the quarter ending 2024-06-30 was $16.05K, a 44.44% decline year-over-year.
- REVELATION BIOSCIENCES, INC. operating lease, expense for the quarter ending 2024-03-31 was $16.05K, a 35.78% decline year-over-year.
- REVELATION BIOSCIENCES, INC. operating lease, expense for fiscal 2024 was $64.20K, a 42.50% decline from fiscal 2023.
- REVELATION BIOSCIENCES, INC. operating lease, expense for fiscal 2023 was $111.66K, a 67.55% increase from fiscal 2022.
- REVELATION BIOSCIENCES, INC. operating lease, expense for fiscal 2022 was $66.64K, a 20.63% increase from fiscal 2021.
- REVELATION BIOSCIENCES, INC. operating lease, expense for fiscal 2021 was $55.25K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $16.05K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $32.10K derived: sum of 2 quarters · filed 2025-03-06 | $48.15K derived: sum of 3 quarters · filed 2025-03-06 | $64.20K 10-K · filed 2025-03-06 |
| 2024-09-30 | $16.05K 10-Q · filed 2024-11-08 | $32.10K derived: sum of 2 quarters · filed 2024-11-08 | $48.15K 10-Q · filed 2024-11-08 | $77.04K derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-06-30 | $16.05K 10-Q/A · filed 2024-09-23 | $32.10K 10-Q/A · filed 2024-09-23 | $60.99K derived: sum of 3 quarters · filed 2025-03-06 | $89.88K derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-03-31 | $16.05K 10-Q/A · filed 2024-09-23 | $44.94K derived: sum of 2 quarters · filed 2025-03-06 | $73.83K derived: sum of 3 quarters · filed 2025-03-06 | $102.72K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-12-31 | $28.89K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $57.78K derived: sum of 2 quarters · filed 2025-03-06 | $86.67K derived: sum of 3 quarters · filed 2025-03-06 | $111.66K 10-K · filed 2025-03-06 |
| 2023-09-30 | $28.89K 10-Q · filed 2024-11-08 | $57.78K derived: sum of 2 quarters · filed 2024-11-08 | $82.77K 10-Q · filed 2024-11-08 | $99.96K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $28.89K 10-Q/A · filed 2024-09-23 | $53.88K 10-Q/A · filed 2024-09-23 | $71.07K derived: sum of 3 quarters · filed 2024-09-23 | $88.27K derived: sum of 4 quarters · filed 2024-09-23 |
| 2023-03-31 | $24.99K 10-Q/A · filed 2024-09-23 | $42.18K derived: sum of 2 quarters · filed 2024-09-23 | $59.38K derived: sum of 3 quarters · filed 2024-09-23 | $76.57K derived: sum of 4 quarters · filed 2024-09-23 |
| 2022-12-31 | $17.19K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-23 | $34.38K derived: sum of 2 quarters · filed 2024-09-23 | $51.58K derived: sum of 3 quarters · filed 2024-09-23 | $66.64K 10-K/A · filed 2024-09-23 |
| 2022-09-30 | $17.19K 10-Q · filed 2023-11-09 | $34.39K derived: sum of 2 quarters · filed 2023-11-09 | $49.45K 10-Q · filed 2023-11-09 | $64.52K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $17.19K 10-Q · filed 2023-08-11 | $32.26K 10-Q · filed 2023-08-11 | $47.33K derived: sum of 3 quarters · filed 2023-08-11 | $62.39K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $15.07K 10-Q · filed 2023-05-22 | $30.13K derived: sum of 2 quarters · filed 2023-05-22 | $45.20K derived: sum of 3 quarters · filed 2023-05-22 | $60.27K derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $15.07K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $30.13K derived: sum of 2 quarters · filed 2023-03-30 | $45.20K derived: sum of 3 quarters · filed 2023-03-30 | $55.25K 10-K · filed 2023-03-30 |
| 2021-09-30 | $15.07K 10-Q · filed 2022-11-10 | $30.13K derived: sum of 2 quarters · filed 2022-11-10 | $40.18K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $15.07K 10-Q · filed 2022-08-15 | $25.11K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |